Use of Tofacitinib in Difficult to Treat Clinically Amyopathic Dermatomyositis

Clinically amyopathic dermatomyositis, characterized by skin symptoms without muscle involvement, can significantly impair quality of life and is often resistant to conventional treatments. A case report of a 42-year-old woman with this condition, who did not respond to multiple systemic therapies, showed that treatment with tofacitinib 5 mg twice daily led to significant improvement in skin lesions and hair regrowth within 2 months, without notable adverse effects. This suggests that JAK inhibitors like tofacitinib may be a viable option when other treatments fail.